(Q39840013)

English

Combinatorial strategies by marine cyanobacteria: symplostatin 4, an antimitotic natural dolastatin 10/15 hybrid that synergizes with the coproduced HDAC inhibitor largazole

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Combinatorial strategies by marine cyanobacteria: symplostatin 4, an antimitotic natural dolastatin 10/15 hybrid that synergizes with the coproduced HDAC inhibitor largazole (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

1 reference

based on heuristic

inferred from title

1 reference

1 reference

4

object named as

Hendrik Luesch

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

author name string

Kanchan Taori

1

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Yanxia Liu

2

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Valerie J Paul

3

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

publication date

6 July 2009

1 reference

16 September 2022

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

1634-1639

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

The cyanobacterial origin of potent anticancer agents originally isolated from sea hares.

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200900192

21 January 2018

Antifungal cyclic peptides from the terrestrial blue-green alga Anabaena laxa. I. Isolation and biological properties

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.200900192

21 January 2018

New peptolides from the cyanobacterium Nostoc insulare as selective and potent inhibitors of human leukocyte elastase

2 references

9 March 2024

https://opencitations.net/index/api/v1/citations/10.1002/CBIC.200800415

9 March 2024

https://opencitations.net/index/api/v1/references/10.1002/CBIC.200900192

Synthetic lethal screen identification of chemosensitizer loci in cancer cells

1 reference

9 March 2024

https://opencitations.net/index/api/v1/references/10.1002/CBIC.200900192

Total structure and inhibition of tumor cell proliferation of laxaphycins.

1 reference

9 March 2024

https://opencitations.net/index/api/v1/references/10.1002/CBIC.200900192

Total synthesis and molecular target of largazole, a histone deacetylase inhibitor

1 reference

9 March 2024

https://opencitations.net/index/api/v1/references/10.1002/CBIC.200900192

Malevamide D: isolation and structure determination of an isodolastatin H analogue from the marine cyanobacterium Symploca hydnoides

1 reference

9 March 2024

https://opencitations.net/index/api/v1/references/10.1002/CBIC.200900192

Belamide A, a new antimitotic tetrapeptide from a Panamanian marine cyanobacterium

1 reference

9 March 2024

https://opencitations.net/index/api/v1/references/10.1002/CBIC.200900192

Isolation and structure of the cytostatic linear depsipeptide dolastatin 15

1 reference

9 March 2024

https://opencitations.net/index/api/v1/references/10.1002/CBIC.200900192

Structure determination, conformational analysis, chemical stability studies, and antitumor evaluation of the cryptophycins. Isolation of 18 new analogs from Nostoc sp. strain GSV 224

1 reference

9 March 2024

https://opencitations.net/index/api/v1/references/10.1002/CBIC.200900192

Localization of the antimitotic peptide and depsipeptide binding site on beta-tubulin.

1 reference

9 March 2024

https://opencitations.net/index/api/v1/references/10.1002/CBIC.200900192

Interactions of antimitotic peptides and depsipeptides with tubulin

1 reference

9 March 2024

https://opencitations.net/index/api/v1/references/10.1002/CBIC.200900192

Antimalarial peptides from marine cyanobacteria: isolation and structural elucidation of gallinamide A.

1 reference

9 March 2024

https://opencitations.net/index/api/v1/references/10.1002/CBIC.200900192

The molecular pharmacology of symplostatin 1: a new antimitotic dolastatin 10 analog

1 reference

9 March 2024

https://opencitations.net/index/api/v1/references/10.1002/CBIC.200900192

In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer

1 reference

9 March 2024

https://opencitations.net/index/api/v1/references/10.1002/CBIC.200900192

Natural products as sources of new drugs over the last 25 years

1 reference

9 March 2024

https://opencitations.net/index/api/v1/references/10.1002/CBIC.200900192

Symplostatin 3, a new dolastatin 10 analogue from the marine cyanobacterium Symploca sp. VP452

1 reference

9 March 2024

https://opencitations.net/index/api/v1/references/10.1002/CBIC.200900192

Antimitotic peptides and depsipeptides

1 reference

9 March 2024

https://opencitations.net/index/api/v1/references/10.1002/CBIC.200900192

Structure and activity of largazole, a potent antiproliferative agent from the Floridian marine cyanobacterium Symploca sp.

1 reference

9 March 2024

https://opencitations.net/index/api/v1/references/10.1002/CBIC.200900192

Synthesis and biological activity of chimeric structures derived from the cytotoxic natural compounds dolastatin 10 and dolastatin 15.

1 reference

9 March 2024

https://opencitations.net/index/api/v1/references/10.1002/CBIC.200900192

Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy

1 reference

9 March 2024

https://opencitations.net/index/api/v1/references/10.1002/CBIC.200900192

Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions

1 reference

9 March 2024

https://opencitations.net/index/api/v1/references/10.1002/CBIC.200900192

Synthesis and antitumor activity of novel dolastatin 10 analogs

1 reference

9 March 2024

https://opencitations.net/index/api/v1/references/10.1002/CBIC.200900192

Marine natural products and related compounds in clinical and advanced preclinical trials

1 reference

9 March 2024

https://opencitations.net/index/api/v1/references/10.1002/CBIC.200900192

Developing a new resource for drug discovery: marine actinomycete bacteria

1 reference

9 March 2024

https://opencitations.net/index/api/v1/references/10.1002/CBIC.200900192

Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells.

1 reference

9 March 2024

https://opencitations.net/index/api/v1/references/10.1002/CBIC.200900192

Isolation of dolastatin 10 from the marine cyanobacterium Symploca species VP642 and total stereochemistry and biological evaluation of its analogue symplostatin 1.

1 reference

9 March 2024

https://opencitations.net/index/api/v1/references/10.1002/CBIC.200900192

Maculotoxin: a neurotoxin from the venom glands of the octopus Hapalochlaena maculosa identified as tetrodotoxin

1 reference

9 March 2024

https://opencitations.net/index/api/v1/references/10.1002/CBIC.200900192

Symplostatin 1: A dolastatin 10 analogue from the marine cyanobacterium Symploca hydnoides

1 reference

9 March 2024

https://opencitations.net/index/api/v1/references/10.1002/CBIC.200900192

Differential effects of active isomers, segments, and analogs of dolastatin 10 on ligand interactions with tubulin. Correlation with cytotoxicity

1 reference

9 March 2024

https://opencitations.net/index/api/v1/references/10.1002/CBIC.200900192

Structure-activity studies with chiral isomers and with segments of the antimitotic marine peptide dolastatin 10

1 reference

9 March 2024

https://opencitations.net/index/api/v1/references/10.1002/CBIC.200900192

The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10

1 reference

9 March 2024

https://opencitations.net/index/api/v1/references/10.1002/CBIC.200900192

Identifiers

10.1002/CBIC.200900192

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39840013&oldid=2099348210"